WO1992013533A1 - Pharmaceutical compositions containing amethocaine - Google Patents

Pharmaceutical compositions containing amethocaine Download PDF

Info

Publication number
WO1992013533A1
WO1992013533A1 PCT/GB1992/000170 GB9200170W WO9213533A1 WO 1992013533 A1 WO1992013533 A1 WO 1992013533A1 GB 9200170 W GB9200170 W GB 9200170W WO 9213533 A1 WO9213533 A1 WO 9213533A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
amethocaine
composition
salt
layer
Prior art date
Application number
PCT/GB1992/000170
Other languages
French (fr)
Inventor
David Graham Boardman
Kevin Maughan
Original Assignee
Smith & Nephew Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith & Nephew Plc filed Critical Smith & Nephew Plc
Priority to EP92903123A priority Critical patent/EP0522122B1/en
Priority to GB9219079A priority patent/GB2258397B/en
Priority to DK92903123T priority patent/DK0522122T3/en
Priority to DE69232014T priority patent/DE69232014T2/en
Priority to AT92903123T priority patent/ATE204474T1/en
Priority to CA002078885A priority patent/CA2078885C/en
Priority to AU11787/92A priority patent/AU652226B2/en
Publication of WO1992013533A1 publication Critical patent/WO1992013533A1/en
Priority to US08/287,470 priority patent/US5580901A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Definitions

  • the present invention relates to pharmaceutical compositions and more particularly to compositions useful for topical anaesthesia.
  • Amethocaine (2-dimethylaminoethyl p-butyl aminobenzoate) is used in topical preparations to provide percutaneous anaesthesia.
  • Topical percutaneous anaesthetic compositions containing amethocaine base which are the form of aqueous gels are disclosed in GB-2163956-A.
  • amethocaine base is but sparingly soluble in water, dispersions in water will have pH values typically from pH 8 to 11 and under these pH conditions have a high rate of hydrolysis. It has been proposed to stabilise amethocaine by the addition of acids to produce salts and it has been demonstrated that salts such as the hydrochloride exhibit maximum stability at pH values of between pH 3 and 4. However, use of amethocaine salts for storage stability denies the user the benefits which accrue by the use of amethocaine free base.
  • hydrated amethocaine base may be formulated into storage stable gel formulations suitable for percutaneous anaesthetic use.
  • a pharmaceutical composition suitable for percutaneous anaesthesia comprising amethocaine, an aqueous gelling agent and a pharmaceutically acceptable salt in an amount of from 1 to 30% by weight of the composition wherein the pH of the composition is not less than pH 7.0.
  • the present invention provides a process for the preparation of such anaesthetic compositions which comprises mixing together amethocaine, a gelling agent and a pharmaceutically acceptable salt in an amount of from 1 to 30% by weight of the composition, and maintaining the pH of the mixture at a pH of not less than pH 7.0.
  • the concentration of salt employed is that which will reduce the aqueous solubility of amethocaine base significantly, for example from 25% to 100% when adjusted to a buffered pH range of 7.0 - 10.0.
  • salt concentrations of from 1 to 30% will fulfil this criterion.
  • the salt concentration will be not less than 5% w/w.
  • the salt concentration need not normally exceed about 25% w/w.
  • the salt will be present in an amount of from 5 to 25%, more suitably less than about 10%.
  • the salt concentration will be about 5%.
  • compositions of the present invention will have a pH value of pH 7.0 or above. pH values within this range may be achieved by the use of suitable buffering agents. Aptly the pH range will be less than 10 and more aptly will be in the range of pH 7.5 - 8.5. More aptly the pH range will be from 7.4 to 8.4 and preferably will be about pH 7.7.
  • the buffering agents which may be employed in the practice of the present invention may include any of those known for this purpose. Apt buffering agents for use in the present invention include inorganic and organic buffering agents such as the phosphate, borate and citrophosphate buffers.
  • the amethocaine is present in the composition, as the hydrated free base in amounts generally greater than 1% by weight of the total composition.
  • the amount of amethocaine generally need not exceed 10% w/w since amounts greater than this would not normally be expected to increase the anaesthetic effect.
  • the amethocaine concentration will be from 1 - 10% w/w, more aptly from 2 - 6% w/w.
  • the amethocaine concentration will be about 4%.
  • the gelling agent employed in the composition of the invention may be any of those conventionally employed and which are stable under the pH conditions employed. The gelling agent should have suitable rheological properties for its intended use.
  • Suitable gelling agents include methyl cellulose, hydroxy ethyl cellulose, carbomers and other pharmaceutically acceptable thickening agents such as xanthan gum.
  • the salts employed in the composition of the invention need to be both water soluble and either neutral or able to be buffered to a pH of 7.0 or above.
  • the salts may contain organic or inorganic anion ⁇ .
  • Apt inorganic ions include sulphate, borate, phosphate, nitrate carbonte or helide.
  • Apt organic anions will include acetate and citrate.
  • the salt cation may be an alkali or alkaline earth metal or iron.
  • Apt salts for use in the invention include sodium and potassium chlorides and other halides, and magnesium sulphate.
  • the amethocaine maybe employed directly in the form of the free base.
  • the free base may be generated iri situ by incorporating an amethocaine salt, eg. the hydrochloride and a suitable base eg. sodium hydroxide into the gel formulation.
  • an amethocaine salt eg. the hydrochloride and a suitable base eg. sodium hydroxide
  • Some salt will be formed as a result of the reaction between the amethocaine salt and the base, which will contribute to the salt level in the formulation.
  • Salts used as buffering agents in the gel formulations may also contribute to the total salt concentration in the gel formulation of the invention.
  • composition of the present invention may be prepared and packaged under sterile conditions.
  • suitable antimicrobial agents may be incorporated into the formulations as preservatives.
  • composition of the present invention may be packaged in a dispenser, suitably a tube.
  • the dispenser is adapted to deliver unit dose quantities of the anaesthetic, for example the composition is packaged in a tube whose volume is equivalent to one unit dose.
  • compositions may be presented in the form of a dressing comprising a skin-conformable backing layer having on its skin facing surface, a skin contacting layer of a composition in accordance with the invention.
  • the presentation may be in the form of an adhesive dressing wherein the skin contacting layer of anaesthetic composition is inset from the edges of the conformable body layer and the free area of the skin facing surface has a layer of adhesive thereon.
  • the anaesthetic layer is inset from all the edges of the backing layer and is surrounded by a layer of adhesive.
  • compositions of the invention it is desirable to store the compositions of the invention at a temperature below the melting point of the hydrated amethocaine base (32°C). Aptly the composition will be stored at temperatures greater than 5°C, more aptly the compositions of the invention will be stored at a temperature between 5 to 30°C. Suitably the compositions of the invention will be stored at a temperature of from 5 to 15°C.
  • compositions of the invention have been shown to exhibit good storage stability with low amethocaine decomposition even at relatively high storage temperatures.
  • compositions of the invention may be applied directly to the skin for inducing topical anaesthesia.
  • Amethocaine Base (%w/w) 4.0 4.0 4.0
  • Formulation 3 is an example of the invention. The other formulations are controls.
  • Gel compositions suitable for percutaneous anaesthesia were prepared by mixing the following:
  • Amethocaine Hydrochloride 4.55% w/w Sodium Hydroxide 0.605% w/w Sodium Chloride 5.0% w/w Xanthan Gum 1.0% w/w Deionised water* qsl00%*
  • the formulated gel exhibited satisfactory stability and rheological properties.
  • compositions derived from amethocaine hydrochloride were prepared according to the following formulations:-
  • compositions were then subjected to ageing at 25 ⁇ C for 9 weeks and analysed for decomposition products as described in Example 1 and are also reported above.
  • Gel compositions A-I were made up according to the formulations shown in the following table and tested for storage stability over a period of 9 weeks at a temperature of 25°C. With the exception of Composition A, the formulations were either pH adjusted (formulation B to D) or were buffered to about pH 7.5. The chemical stability was determined by measuring the decomposition to butylp-amino benzoic acid, as described in Example 1.
  • compositions D to G are examples of the invention whereas compositions A to C, H and I are included for control purposes.
  • Formulations A to D were designed to examine the effects of adjustment of pH and inclusion of salt on gel composition exemplified by Patent Specification GB 2163956-A (corresponds to formulation A).
  • the data on rate of decomposition show that whilst adjustment of pH to 7.5 and inclusion of salt at 0.5% level did not lead to a reduction in the decomposition rate, presence of salt at 5% level (formulation D) resulted in a significant reduction in the degree of decomposition of amethocaine.
  • Formulations E and F are examples of the current invention showing markedly reduced levels of decomposition in presence of salts other than sodium chloride, namely magnesium sulphate and sodium acetate, respectively.
  • Formulations E and G also illustrate the use of an organic buffer (Tris buffer) instead of the phosphate buffer to achieve a pH of about 7.5.
  • Tris buffer an organic buffer
  • a comparison of the decomposition rate in formulation G, which was buffered using Tris buffer and contained 10% sodium chloride with that in formulation C of Example 2 which also contained 10% sodium chloride but was buffered using the phosphate buffer shows that the nature of buffer had no demonstratable effect on the rate of decomposition of amethocaine.
  • the pH and presence of salt were shown to be the critical factors for reducing the rate of decomposition of amethocaine, in accordance with the invention.
  • Formulations H and I were prepared with a final concentration of amethocaine base of 2% to illustrate the effects of starting with amethocaine base or generating the base ij situ by neutralising amethocaine hydrochloride with sodium hydroxide in its formulation.
  • the small amount (about 0.5%) of sodium chloride generated in the latter formulation was shown not to have a significant effect on the rate of decomposition of amethocaine.

Abstract

A storage stable composition for topical anaesthesia comprises amethocaine and a pharmaceutically acceptable salt present in amount of from 1 to 30 % by weight of the composition, which composition has a pH of not less than pH 7.0.

Description

PHARMACEUTICAL COMPOSITIONS CONTAINING AMETHOCAINE
The present invention relates to pharmaceutical compositions and more particularly to compositions useful for topical anaesthesia.
Amethocaine (2-dimethylaminoethyl p-butyl aminobenzoate) is used in topical preparations to provide percutaneous anaesthesia. Topical percutaneous anaesthetic compositions containing amethocaine base which are the form of aqueous gels are disclosed in GB-2163956-A.
Although amethocaine base is but sparingly soluble in water, dispersions in water will have pH values typically from pH 8 to 11 and under these pH conditions have a high rate of hydrolysis. It has been proposed to stabilise amethocaine by the addition of acids to produce salts and it has been demonstrated that salts such as the hydrochloride exhibit maximum stability at pH values of between pH 3 and 4. However, use of amethocaine salts for storage stability denies the user the benefits which accrue by the use of amethocaine free base.
We have now found that hydrated amethocaine base may be formulated into storage stable gel formulations suitable for percutaneous anaesthetic use.
According to the present invention there is provided a pharmaceutical composition suitable for percutaneous anaesthesia, comprising amethocaine, an aqueous gelling agent and a pharmaceutically acceptable salt in an amount of from 1 to 30% by weight of the composition wherein the pH of the composition is not less than pH 7.0.
The present invention provides a process for the preparation of such anaesthetic compositions which comprises mixing together amethocaine, a gelling agent and a pharmaceutically acceptable salt in an amount of from 1 to 30% by weight of the composition, and maintaining the pH of the mixture at a pH of not less than pH 7.0.
The concentration of salt employed is that which will reduce the aqueous solubility of amethocaine base significantly, for example from 25% to 100% when adjusted to a buffered pH range of 7.0 - 10.0. Generally salt concentrations of from 1 to 30% will fulfil this criterion. Aptly the salt concentration will be not less than 5% w/w. The salt concentration need not normally exceed about 25% w/w. Thus aptly the salt will be present in an amount of from 5 to 25%, more suitably less than about 10%. Typically the salt concentration will be about 5%.
The compositions of the present invention will have a pH value of pH 7.0 or above. pH values within this range may be achieved by the use of suitable buffering agents. Aptly the pH range will be less than 10 and more aptly will be in the range of pH 7.5 - 8.5. More aptly the pH range will be from 7.4 to 8.4 and preferably will be about pH 7.7. The buffering agents which may be employed in the practice of the present invention may include any of those known for this purpose. Apt buffering agents for use in the present invention include inorganic and organic buffering agents such as the phosphate, borate and citrophosphate buffers.
The amethocaine is present in the composition, as the hydrated free base in amounts generally greater than 1% by weight of the total composition. The amount of amethocaine generally need not exceed 10% w/w since amounts greater than this would not normally be expected to increase the anaesthetic effect. Aptly the amethocaine concentration will be from 1 - 10% w/w, more aptly from 2 - 6% w/w. Typically the amethocaine concentration will be about 4%. The gelling agent employed in the composition of the invention may be any of those conventionally employed and which are stable under the pH conditions employed. The gelling agent should have suitable rheological properties for its intended use. Thus, it should have a shear-dependent viscosity high enough for it to maintain its physical integrity on storage and yet low enough to permit it to be filled into suitable dispensers to be expelled from the dispensers at the point of use and to be readily spread over the skin. Suitable gelling agents include methyl cellulose, hydroxy ethyl cellulose, carbomers and other pharmaceutically acceptable thickening agents such as xanthan gum.
The salts employed in the composition of the invention need to be both water soluble and either neutral or able to be buffered to a pH of 7.0 or above. The salts may contain organic or inorganic anionε. Apt inorganic ions include sulphate, borate, phosphate, nitrate carbonte or helide. Apt organic anions will include acetate and citrate. The salt cation may be an alkali or alkaline earth metal or iron. Apt salts for use in the invention include sodium and potassium chlorides and other halides, and magnesium sulphate.
In preparing the compositions of the invention, the amethocaine maybe employed directly in the form of the free base. Alternatively the free base may be generated iri situ by incorporating an amethocaine salt, eg. the hydrochloride and a suitable base eg. sodium hydroxide into the gel formulation. Some salt will be formed as a result of the reaction between the amethocaine salt and the base, which will contribute to the salt level in the formulation. Salts used as buffering agents in the gel formulations may also contribute to the total salt concentration in the gel formulation of the invention.
The composition of the present invention may be prepared and packaged under sterile conditions. Alternatively, suitable antimicrobial agents may be incorporated into the formulations as preservatives.
Aptly the composition of the present invention may be packaged in a dispenser, suitably a tube. Similarly, the dispenser is adapted to deliver unit dose quantities of the anaesthetic, for example the composition is packaged in a tube whose volume is equivalent to one unit dose.
Alternatively the compositions may be presented in the form of a dressing comprising a skin-conformable backing layer having on its skin facing surface, a skin contacting layer of a composition in accordance with the invention.
Aptly, the presentation may be in the form of an adhesive dressing wherein the skin contacting layer of anaesthetic composition is inset from the edges of the conformable body layer and the free area of the skin facing surface has a layer of adhesive thereon. Preferably, the anaesthetic layer is inset from all the edges of the backing layer and is surrounded by a layer of adhesive.
It is desirable to store the compositions of the invention at a temperature below the melting point of the hydrated amethocaine base (32°C). Aptly the composition will be stored at temperatures greater than 5°C, more aptly the compositions of the invention will be stored at a temperature between 5 to 30°C. Suitably the compositions of the invention will be stored at a temperature of from 5 to 15°C.
The compositions of the invention have been shown to exhibit good storage stability with low amethocaine decomposition even at relatively high storage temperatures.
The compositions of the invention may be applied directly to the skin for inducing topical anaesthesia.
The invention will now be illustrated by the following Examples.
Example 1
Three formulations were prepared as follows:
Amethocaine Base (%w/w) 4.0 4.0 4.0
Hydroxyethyl cellulose (%w/w) 1.5 1.5 1.0
Sodium Chloride (%w/w) 24.0
Dionised Water (%w/w) qslOO qslOO qslOO pH 9.4 7.6(buffered) 9.4
Formulation 3 is an example of the invention. The other formulations are controls.
Samples of each formulation were then aged for 9 weeks at 5°C, 12°C and 25°C respectively, after which each sample was analysed using High Performance liquid chromotography to determine the percentage decomposition of the amethocaine to butyl p-amino benzoic acid. The results are given in the following table: Formulation % Decomposition pH
5°C 12°C 25°C
Figure imgf000010_0001
It will be seen from the foregoing results that the stability of the amethocaine hydrate compositions in accordance with the present invention can be achieved at high pH values.
Example 2
Gel compositions suitable for percutaneous anaesthesia were prepared by mixing the following:
Amethocaine Hydrochloride 4.55% w/w Sodium Hydroxide 0.605% w/w Sodium Chloride 5.0% w/w Xanthan Gum 1.0% w/w Deionised water* qsl00%*
* a buffering agent was included to buffer the pH of the gel to pH 7.6.
The formulated gel exhibited satisfactory stability and rheological properties.
Example 3
Other anaesthetic compositions derived from amethocaine hydrochloride were prepared according to the following formulations:-
wt% of Composition A B C D
Amethocaine Hydrochloride 4.6 4.6 4.6 4.6 Sodium Hydroxide 1.3 1.3 1.3 1.3
Sodium Chloride 5.0 5.0 10.0 10.0
Xanthan Gum 1.0 2.0 1.0 2.0
Potassium Dihydrogen Phosphate 2.9 2.9 2.9 2.9 Deionised Water qslOO qslOO qslOO qslOO pH 7.6 7.5 7.5 7.7
% decomposition 3.1 2.9 1.9 1.9
Each of the compositions were then subjected to ageing at 25βC for 9 weeks and analysed for decomposition products as described in Example 1 and are also reported above.
These results further demonstrate the effect of inclusion of sodium chloride with Formulations C and D containing 10% sodium chloride showing only 1.9% decomposition of amethocaine compared to about 3% decomposition in formulations A and B containing 5% sodium chloride. A change in the concentration of Xanthan Gum from 1% to 2% did not result in a change in the rate of decomposition, indicating that the viscosity of the formulation does not influence the rate of decomposition of amethocaine.
Example 4
Gel compositions A-I were made up according to the formulations shown in the following table and tested for storage stability over a period of 9 weeks at a temperature of 25°C. With the exception of Composition A, the formulations were either pH adjusted (formulation B to D) or were buffered to about pH 7.5. The chemical stability was determined by measuring the decomposition to butylp-amino benzoic acid, as described in Example 1.
Compositions D to G are examples of the invention whereas compositions A to C, H and I are included for control purposes. Refe rence A B C D E F G H
Amethocaine Base 4.0 4.0 4.0 4.0 4.0 4.0 4.0 2.0 Amethocaine HC1 2.
NaOH 0.5 0.
HEC* 1.5 1.5 1.5 1.5
Xanthan Gum 1.0 1.0 1.0 1.0 1.
THMA** 2.0 2.0
MgS04 20.0
NaCOOCH3 20.0
NaCl 0.5 5.0 10.0
KH2P04 2.0 2.9 2. pH 9.1 7.5 7.5 7.5 7.5 7.5 7.0 7.6 7. % decomposition 7.5 7.8 7.2 4.0 2.0 0.8 1.9 9.5 8.
* Hydroxyethylcellulose
** Tris(hydroxymethyl)aminomethane
Formulations A to D were designed to examine the effects of adjustment of pH and inclusion of salt on gel composition exemplified by Patent Specification GB 2163956-A (corresponds to formulation A). The data on rate of decomposition show that whilst adjustment of pH to 7.5 and inclusion of salt at 0.5% level did not lead to a reduction in the decomposition rate, presence of salt at 5% level (formulation D) resulted in a significant reduction in the degree of decomposition of amethocaine.
Formulations E and F are examples of the current invention showing markedly reduced levels of decomposition in presence of salts other than sodium chloride, namely magnesium sulphate and sodium acetate, respectively. Formulations E and G also illustrate the use of an organic buffer (Tris buffer) instead of the phosphate buffer to achieve a pH of about 7.5. Furthermore, a comparison of the decomposition rate in formulation G, which was buffered using Tris buffer and contained 10% sodium chloride with that in formulation C of Example 2 which also contained 10% sodium chloride but was buffered using the phosphate buffer shows that the nature of buffer had no demonstratable effect on the rate of decomposition of amethocaine. Thus the pH and presence of salt were shown to be the critical factors for reducing the rate of decomposition of amethocaine, in accordance with the invention.
Formulations H and I were prepared with a final concentration of amethocaine base of 2% to illustrate the effects of starting with amethocaine base or generating the base ij situ by neutralising amethocaine hydrochloride with sodium hydroxide in its formulation. The small amount (about 0.5%) of sodium chloride generated in the latter formulation was shown not to have a significant effect on the rate of decomposition of amethocaine.

Claims

1. A pharmaceutical composition suitable for percutaneous anaesthesia comprising amethocaine, an aqueous gelling agent and a pharmaceutically acceptable salt in amount of from 1 to 30% by weight of the composition wherein the pH of the composition is not less than pH 7.0.
2. A composition according to claim 1 wherein the salt cation is an alkali or alkaline earth metal.
3. A composition as claimed in either claims 1 or 2 wherein salt anion comprises chloride, sulphate, phosphate, borate, acetate or citrate.
4. A composition as claimed in any one of claims 1 to 3 wherein the salt is present in an amount of from 5 to 25% by weight of the composition.
5. A composition according to any one of claims 1 to 4. wherein at least a proportion of the salt component is derived from the reaction of an acid addition salt of amethocaine with a base.
6. A composition according to claim 5 wherein the acid addition salt is the hydrochloride and the base is sodium hydroxide.
7. A composition as claimed in any one of claims 1 to 6 wherein a proportion of the salt component is provided by a buffering agent.
8. A composition according to any one of claims 1 to 8 wherein the pH is maintained at about pH 7.7.
9. A composition according to any one of claims 1 to
8 wherein the gelling agent comprises methyl cellulose, hydroxyethyl cellulose, a carbomer or xanthan gum.
10. A composition according to any one of claims 1 to
9 comprising at least 1% by weight of amethocaine, calculated as the free base.
11. A composition according to any of claims 1 to 10 comprising not more than 10% by weight of amethocaine, calculated as the free base.
12. A process for the preparation of a percutaneous anaesthetic composition according to any of the preceding claims comprising mixing together amethocaine, gelling agent and a pharmacologically acceptable salt and maintaining the pH of the mixture at pH of not less than pH 7.0.
13. A process according to claim 12 wherein the mixture comprises an amethocaine acid addition salt and a base.
14. A percutaneous composition according to one of claims 1 to 11 or as produced according to claim 12 or 13 in a sterilised and packaged form.
15. A composition according to claim 14 packaged in a dispenser.
16. A composition according to claim 15 wherein the dispenser is a tube.
17. A composition according to claim 16 wherein the packaged form comprises a skin-conformable backing layer having on its skin facing surface a skin contacting layer of an anaesthetic composition according to any one of claims 1 to 11.
18. A composition according to claim 17 wherein the layer of anaesthetic is inset from the edges of the backing layer and wherein the skin-facing surface of the backing layer not bearing the anaesthetic layer has a layer of adhesive thereon.
PCT/GB1992/000170 1991-01-30 1992-01-29 Pharmaceutical compositions containing amethocaine WO1992013533A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP92903123A EP0522122B1 (en) 1991-01-30 1992-01-29 Pharmaceutical compositions containing amethocaine
GB9219079A GB2258397B (en) 1991-01-30 1992-01-29 Pharmaceutical compositions containing amethocaine
DK92903123T DK0522122T3 (en) 1991-01-30 1992-01-29 Pharmaceuticals containing amethocaine
DE69232014T DE69232014T2 (en) 1991-01-30 1992-01-29 Medicines containing amethocaine
AT92903123T ATE204474T1 (en) 1991-01-30 1992-01-29 MEDICINAL PRODUCTS CONTAINING AMETHOCAIN
CA002078885A CA2078885C (en) 1991-01-30 1992-01-29 Pharmaceutical compositions containing amethocaine
AU11787/92A AU652226B2 (en) 1991-01-30 1992-01-29 Pharmaceutical compositions containing amethocaine
US08/287,470 US5580901A (en) 1991-01-30 1994-08-08 Pharmaceutical compositions of amethocaine free base

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919101986A GB9101986D0 (en) 1991-01-30 1991-01-30 Pharmaceutical compositions
GB9101986.9 1991-01-30

Publications (1)

Publication Number Publication Date
WO1992013533A1 true WO1992013533A1 (en) 1992-08-20

Family

ID=10689227

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/000170 WO1992013533A1 (en) 1991-01-30 1992-01-29 Pharmaceutical compositions containing amethocaine

Country Status (12)

Country Link
US (2) US5580901A (en)
EP (1) EP0522122B1 (en)
JP (1) JP2650781B2 (en)
AT (1) ATE204474T1 (en)
AU (1) AU652226B2 (en)
CA (1) CA2078885C (en)
DE (1) DE69232014T2 (en)
DK (1) DK0522122T3 (en)
ES (1) ES2162794T3 (en)
GB (2) GB9101986D0 (en)
WO (1) WO1992013533A1 (en)
ZA (1) ZA92607B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585804A1 (en) * 1992-09-03 1994-03-09 Saltrates International S.A. Corn remover containing NaOH
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69711237T2 (en) 1996-10-14 2002-10-17 Kowa Co LOCAL ANESTHETIC FOR EXTERNAL USE
DE19713263C2 (en) 1997-03-29 1999-11-04 Carsten Goldschmidt Use a procaine hydrochloride solution for injection to reduce inflammation
US20040077593A1 (en) * 2002-10-21 2004-04-22 Marron Susan M. Numbing gel for hair removal
ES2223277B1 (en) 2003-06-19 2006-03-01 Fernando Bouffard Fita ANESTHETIC COMPOSITION FOR TOPICAL ADMINISTRATION.
AU2003265624B2 (en) * 2003-08-21 2011-03-31 Abeona Therapeutics Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2016456A1 (en) * 1968-08-27 1970-05-08 Smith & Nephew
GB2163956A (en) * 1984-09-08 1986-03-12 Ile De France Percutaneous anaesthetic composition for topical application
WO1988009169A1 (en) * 1987-05-28 1988-12-01 Smith & Nephew Plc Unit-dose film composition for percutaneous anaesthesia and associated method
EP0336901A2 (en) * 1988-04-04 1989-10-11 Warner-Lambert Company Anesthetic skin moisturizing composition and method of preparing same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1954152A (en) * 1929-12-19 1934-04-10 Winthrop Chem Co Inc Anaesthetic and process of preparing it
US1889645A (en) * 1930-12-22 1932-11-29 Winthrop Chem Co Inc Beta-dimethylaminoethyl ester of para-butylamino-benzoic acid
US2132351A (en) * 1934-07-14 1938-10-04 Winthrop Chem Co Inc Stable aqueous solutions of subtances having an anesthetic effect
US3272700A (en) * 1963-10-03 1966-09-13 Sterling Drug Inc Stabilized aqueous solution of tetracaine salt
US4248855A (en) * 1976-08-27 1981-02-03 Hydrophilics International, Inc. Pharmaceutical base salts
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
US4150114A (en) * 1977-06-13 1979-04-17 The Procter & Gamble Company Dermatological compositions
SE7713618L (en) * 1977-12-01 1979-06-02 Astra Laekemedel Ab LOCAL ANESTHETIC MIXTURE
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
JPS6191137A (en) * 1984-10-11 1986-05-09 Kao Corp External drug composition
US4599354A (en) * 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
US5234957A (en) * 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5209724A (en) * 1988-04-11 1993-05-11 Dhaliwal Avtar S Composite anesthetic article and method of use
US5149320A (en) * 1988-04-11 1992-09-22 Dhaliwal Avtar S Composite anesthetic article and method of use
US5120545A (en) * 1990-08-03 1992-06-09 Alza Corporation Reduction or prevention of sensitization to drugs
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
SE9102890D0 (en) * 1991-10-07 1991-10-07 Hans Evers INSEKTSREPELLERINGSMEDEL

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2016456A1 (en) * 1968-08-27 1970-05-08 Smith & Nephew
GB2163956A (en) * 1984-09-08 1986-03-12 Ile De France Percutaneous anaesthetic composition for topical application
WO1988009169A1 (en) * 1987-05-28 1988-12-01 Smith & Nephew Plc Unit-dose film composition for percutaneous anaesthesia and associated method
EP0336901A2 (en) * 1988-04-04 1989-10-11 Warner-Lambert Company Anesthetic skin moisturizing composition and method of preparing same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585804A1 (en) * 1992-09-03 1994-03-09 Saltrates International S.A. Corn remover containing NaOH
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby

Also Published As

Publication number Publication date
US5580901A (en) 1996-12-03
AU1178792A (en) 1992-09-07
ZA92607B (en) 1992-12-30
US5733930A (en) 1998-03-31
DE69232014D1 (en) 2001-09-27
EP0522122B1 (en) 2001-08-22
CA2078885A1 (en) 1992-07-31
GB9101986D0 (en) 1991-03-13
ES2162794T3 (en) 2002-01-16
AU652226B2 (en) 1994-08-18
EP0522122A1 (en) 1993-01-13
JP2650781B2 (en) 1997-09-03
DE69232014T2 (en) 2002-05-29
DK0522122T3 (en) 2001-12-10
GB9219079D0 (en) 1992-11-04
JPH05505405A (en) 1993-08-12
GB2258397A (en) 1993-02-10
CA2078885C (en) 2002-03-19
ATE204474T1 (en) 2001-09-15
GB2258397B (en) 1994-11-09

Similar Documents

Publication Publication Date Title
JP5714202B2 (en) Stabilized oxygen release composition
CA2665611C (en) Stabilized prostaglandin e composition
KR20180001587A (en) Stabilized ophthalmic galactomannan formulations
CA2557795A1 (en) Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose
JP2555555B2 (en) Antifungal topical formulation
US5580901A (en) Pharmaceutical compositions of amethocaine free base
PT1411768E (en) Disinfectant solution based on sodium hypochlorite, and process for preparing it
US5422102A (en) Antiinflammatory and analgesic gel preparation
US5575995A (en) Ferric subsulfate gel and methods of using same
JPWO2018221487A1 (en) Injection containing eribulin or a pharmaceutically acceptable salt thereof
JPS6030646B2 (en) Method for stabilizing skin treatment compositions
WO2005112909A1 (en) Anti-inflammatory analgesic external aqueous liquid preparation
JPH0735342B2 (en) Azulene-containing liquid
JPS6328403B2 (en)
HU184890B (en) Process for preparing an antimicrobial composition with increa sed staaility
JPH075456B2 (en) Eye drops
JPH0780760B2 (en) Stabilized phenylephrine liquid agent
JP3042702B2 (en) Solution for injection and method for preparing the same
JP2844132B2 (en) Antibacterial cream preparation for external use on skin
JP2004182719A (en) Stable eye lotion containing latanoprost as active ingredient
JP2003171204A (en) Gel-like insect repellent formulation
US3274057A (en) Stable hexylresorcinol compositions
JPH09208464A (en) Antimycotic composition for external use
AU2014201174B2 (en) Stabilized prostaglandin e composition
EP1028731A2 (en) Stable antiandrogenic gel composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 1992903123

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2078885

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1992903123

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992903123

Country of ref document: EP